FDA advisory committee recommends (10-0) approval of CTL nineteen (tisagenlecleucel) CAR-T therapy, for the treatment of relapsed or refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia.-Novartis
Added
one month ago on fourteen July two thousand seventeen
Data from Pharmawand – Curated by Toby Galbraith – Date added 14 July 2017